Prelude Therapeutics Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Prelude is a clinical-stage precision oncology company developing small-molecule cancer therapies. It had no product revenue and reported operating losses.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $22.4 million | $9.8 million | $38.9 million | $18.3 million |
| General and administrative expense | $5.5 million | $1.7 million | $11.0 million | $2.9 million |
| Total operating expenses | $27.9 million | $11.4 million | $49.9 million | $21.2 million |
| Net loss | $26.9 million | $11.4 million | $48.2 million | $20.9 million |
| Net loss per share, basic and diluted | $0.58 | $5.50 | $1.06 | $10.65 |
- Q2 R&D increased $12.6 million year over year, primarily from clinical research and chemistry, manufacturing and other costs for PRT543, PRT811 and PRT1419. Six-month R&D rose $20.6 million, mainly due to PRT543 and PRT811 development. G&A growth reflected higher headcount, professional fees and public-company costs.
- Other income was $1.1 million in Q2 and $1.7 million for the first half, largely reflecting Delaware research and development tax credits.
- Operating cash use was $36.1 million for the first half, compared with $18.8 million in 2020. Investing cash use was $1.4 million; financing provided $162.2 million, chiefly from a January common-stock offering that generated $161.4 million net proceeds.
- Cash and cash equivalents were $343.1 million at June 30, 2021, versus $218.3 million at year-end 2020. Total liabilities were $15.2 million, including operating lease liabilities; the filing reports no credit facility or committed capital source. Accumulated deficit was $155.6 million.
- No meaningful operating margin is available because the company had no revenue. Loss per share comparisons are affected by the substantially different weighted-average share counts, including the 2021 public offering.
Business developments, outlook and risks
- Management said existing cash was expected to fund operating expenses and capital expenditures into mid-2023, based on assumptions that could prove inaccurate. Prelude expects significant expenses and losses to continue and may need additional financing; equity financing could dilute shareholders, while other funding arrangements could restrict operations or require rights to be shared.
- PRT543, a PRMT5 inhibitor, remained in Phase 1 dose escalation and biomarker-selected expansion cohorts were enrolling. Management reported an ongoing confirmed complete response in one patient with HRD-positive high-grade serous ovarian cancer after nine months of therapy. Data from dose escalation were anticipated at an oncology meeting in October 2021, with expansion-cohort updates expected during 2022.
- PRT811, a brain-penetrant PRMT5 inhibitor, was in Phase 1. The filing reported a partial response in a refractory glioblastoma patient, with tumor reduction improving to 77% from baseline at week 18. Expansion in selected central nervous system cancers was expected to begin in Q3 2021; further data were anticipated during 2022.
- PRT1419, an MCL1 inhibitor, was in Phase 1 oral dose escalation for hematologic malignancies; dose expansion and combination cohorts were expected in the second half of 2021. A Phase 1 study of its intravenous formulation was underway in solid tumors.
- Clinical observations are preliminary and from early-stage trials; they do not establish efficacy or predict later trial outcomes. Safety, enrollment, regulatory review, manufacturing capacity, competition, intellectual-property protection and access to financing are material risks.
- Management said programs and research activities remained on track despite COVID-19, but disclosed limited trial-site initiation, participation and enrollment delays and cautioned that further disruption could affect trial timelines and costs.
- The company reported no material pending legal proceedings and concluded disclosure controls were effective at a reasonable-assurance level as of June 30, 2021.
Key facts for investors to verify
- Whether clinical-trial enrollment, safety findings and response data for PRT543, PRT811 and PRT1419 support the stated development plans; confirm final, updated data rather than relying on interim observations.
- Whether the projected cash runway into mid-2023 remains reasonable as clinical and manufacturing spending grows; track quarterly operating cash use and financing needs.
- Progress and timing of PRT543 and PRT811 expansion cohorts, the PRT1419 IV and oral studies, and the planned preclinical-to-clinical transitions.
- Potential effects of COVID-19, third-party CRO and manufacturer dependence, and competing oncology programs on trial enrollment, supply and timelines.